Clinical Trials · NCT03883776
Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Enrollment
- 12
- Start date
- Apr 2019
- Locations
- 1 site, Belgium
- Primary endpoint
- Potential of Al18F-NOTA-octreotide as somatostatin receptor PET imaging tracer in patients with neuroendocrine tumors